Imago Biosciences Inc

Imago Biosciences — Investor Presentation (December 2021)

21 slides from Imago Biosciences's investor presentation, Dec 13, 2021

  1. Slide 1: Virtual Investor Event ASH 2021

    VIRTUAL INVESTOR EVENT ASH 2021 December 2021 Exhibit 99.5

  2. Slide 2: Forward-looking statements

    This presentation and the accompanying oral presentation by Imago BioSciences, Inc. (“Imago,” the “Company,” “we,” “us” or similar terms) contains forward looking statements. These statements may relate to, but are not limited to, the results, conduct, progress and timing of Imago clinical trials, t

  3. Slide 3: What's New at ASH? Major Update on ET Program

    1. Yacoub et al. 2019; 2. Harrison et al. 2017; 3. Mills et al. 1999 *platelet count ≤400 x 109/L. Bomedemstat is active across all patients enrolled Preliminary data show durable hematologic responses (response >12 weeks) What’s New at ASH? Major Update on ET Program: Preliminary hematologic respon

  4. Slide 4: Introduction to Bomedemstat

    Introduction to Bomedemstat Bomedemstat is an irreversible inhibitor of LSD1 Discovered and developed by Imago PK and dose-response data support once-daily dosing No apparent penetration across the blood-brain barrier Bomedemstat has been evaluated in 170+ patients with advanced myeloid malignancies

  5. Slide 5: LSD1 is a Key Regulator of Hematopoietic Differentiation

    LSD1 is a Key Regulator of Hematopoietic Differentiation LSD1 (Lysine-specific demethylase 1) demethylates H3K4 and other chromatin-associated proteins, e.g., p53 Loss of LSD1 activity is associated with loss of self-renewal in malignant HSCs1 LSD1 is required for the differentiation of megakaryocyt

  6. Slide 6: ET Study Design

    Safety and tolerability Platelet count reduction (≤400 x 109/L) in the absence of thromboembolic events ET Study Design Primary Endpoints Key Eligibility Criteria Secondary Endpoints Symptom reduction (MPN-SAF TSS) Durability of platelet and WBC count reduction Changes in mutant allele frequencies (

  7. Slide 7: Safety and Tolerability

    Bomedemstat is generally well-tolerated with few Grade 3/4 AEs (3.6%; 12/335) Most common AE was dysgeusia – all events were Grade 1/2 with 2/18 leading to treatment discontinuation Eight SAEs, two of which were related, and both led to dose interruption (thrombocytopenia and mouth haemorrhage) One

  8. Slide 8: Reduction in platelet count in patients treated >6 weeks

    In the 29 patients treated for >6 weeks: 100% patients experienced a reduction in platelets 93% of patients achieved a platelet count of ≤400 x 109/L Response Rate*: 90% (26/29) Primary Objective: Reduction in Platelet Count Mean Platelet Count (±95% CI) N=33 Platelet Count x 109/L Weeks of treatmen

  9. Slide 9: Mean reduction in platelet count and durability of response

    In the 27 patients treated for at least 12 weeks: Mean reduction of 496 x 109/L at Week 12 (N=27) Durability of response: To date, 52% of patients achieved 12 consecutive weeks ≤400 x 109/L Primary Objective: Reduction in Platelet Count *Patient off drug for up to 6 weeks Platelet Count x 109/L Indi

  10. Slide 10: Platelet Responses Across Mutation Status

    Platelet Responses Across Mutation Status Mutation No. of Patients* Mean Baseline Platelet Count (x109/L) Platelet Count Response (%) All Pts 30 838 93% CALR 13 993 100% JAK2V617F 13 765 83% Triple Negative 2 524 100% *Patients with mutation status and platelet counts available Patients with CALR mu

  11. Slide 11: Lowers WBC and Maintains Hemoglobin Levels

    Lowers WBC and Maintains Hemoglobin Levels Mean WBC (±95% CI) N=33 Mean Hemoglobin (±95% CI) N=32 Hemoglobin g/dL WBC Count x 109/L Weeks of treatment Weeks of treatment

  12. Slide 12: Reduction in Total Symptom Score

    Reduction in Total Symptom Score TSS % Change at 24 weeks (Patients with TSS >0 at Day 1, N=17) N at Day 1 with Score >0 = 31 NB 1 excluded (012-202) Source Imago interim, unaudited and ongoing Phase 2 data of Investigational Product 71% had a decrease in TSS 53% had a decrease of >50% 47% had a dec

  13. Slide 13: Conclusions of the ET Study

    Conclusions of the ET Study Bomedemstat (IMG-7289) is generally well tolerated in patients with ET Majority of AEs were low-grade Bomedemstat as monotherapy demonstrates significant clinical activity: Normalization of platelet and WBC counts while maintaining hemoglobin Symptomatic improvement for s

  14. Slide 14: Myelofibrosis Phase 2b Update

    Myelofibrosis Phase 2b Update

  15. Slide 15: Changes in MPN-SAF TSS in Patients with Significant Symptom Burden

    Changes in MPN-SAF TSS – Patients with significant symptom burden (≥20) Total Symptom Score (TSS) at 24 weeks % Change @ 24 ± 2 weeks 17/23 (74%) had a decrease in TSS 6/23 (26%) had a decrease of ≥50% Absolute Change @ 24 ± 2 weeks

  16. Slide 16: Improvements in Hemoglobin in Transfusion-Independent Patients

    * Exclusions due to: Early Termination prior to Wk12 Improvements in Hemoglobin (Hb) In patients (N=36*) who were transfusion-independent at baseline, at 12 weeks: 89% (32/36) had stable or improved Hb 44% (16/36) had an increase ≥1.0 g/dL 44% (16/36) Patients had stable Hb ∆ <±1.0 g/dL Improvements

  17. Slide 17: Impact on Mutant Allele Frequencies in MF

    39% (58/149) of Mutant Alleles showed a reduction of >10% 38% of Mutant Alleles were stable (+/- 10%) for up to >600 days 21% of Mutant Alleles increased in frequency Of secondary high-risk mutations (HRM) for AML: ASXL1 was most sensitive to bomedemstat: 45% had a decrease; 45% were stable over the

  18. Slide 18: Overall Clinical Activity of Bomedemstat

    Overall Clinical Activity of Bomedemstat Bomedemstat is generally well tolerated in all patients 170+ patients with AML, MDS, MF and ET treated to date Majority of AEs have been low-grade; few related SAEs Bomedemstat as monotherapy demonstrates significant clinical activity: Dosing titration allows

  19. Slide 19: Positions Bomedemstat for Potential Phase Success in ET

    Positions Bomedemstat for Potential Phase 3 Success in ET Bomedemstat shows high level of activity on platelets, WBCs, and symptoms Planned P3 patient population to be very similar to those in the P2 Understanding with the FDA on the P3 composite primary endpoint EOP2 meeting with FDA planned for 2H

  20. Slide 20: 2022 Catalysts

    2022 Catalysts Interactions with the FDA and EMA Initiation of new monotherapy and combination trials Updates at EHA and ASH on MF and ET studies

  21. Slide 21: Thank You

    IMAGO BIOSCIENCES THANK YOU

Imago BioSciences — Investor Presentation (December 2021) on 6ix